{"pmid":32454456,"title":"Endocrinology in the time of COVID-19: Diagnosis and Management of Gestational Diabetes Mellitus.","text":["Endocrinology in the time of COVID-19: Diagnosis and Management of Gestational Diabetes Mellitus.","The COVID-19 pandemic has required rapid transformation and adaptation of healthcare services. Women with gestational diabetes mellitus (GDM) are one of the largest high-risk groups accessing antenatal care. In reformulating the care offered to those with GDM, there is a need to balance the sometimes competing requirement of lowering the risk of direct viral transmission against the potential adverse impact of service changes. We suggest pragmatic options for screening of GDM in a pandemic setting based on blood tests, and risk calculators applied to underlying risk factors. Alternative models for antenatal care provision for women with GDM, including targeting high-risk groups, early lifestyle interventions and remote monitoring are provided. Testing options and their timing for postpartum screening in women who had GDM are also considered. Our suggestions are only applicable in a pandemic scenario; usual guidelines and care pathways should be re-implemented as soon as possible and appropriate.","Eur J Endocrinol","Thangaratinam, Shakila","Cooray, Shamil D","Sukumar, Nithya","Huda, Mohammed S","Devlieger, Roland","Benhalima, Katrien","McAuliffe, Fionnuala","Saravanan, Ponnusamy","Teede, Helena","32454456"],"abstract":["The COVID-19 pandemic has required rapid transformation and adaptation of healthcare services. Women with gestational diabetes mellitus (GDM) are one of the largest high-risk groups accessing antenatal care. In reformulating the care offered to those with GDM, there is a need to balance the sometimes competing requirement of lowering the risk of direct viral transmission against the potential adverse impact of service changes. We suggest pragmatic options for screening of GDM in a pandemic setting based on blood tests, and risk calculators applied to underlying risk factors. Alternative models for antenatal care provision for women with GDM, including targeting high-risk groups, early lifestyle interventions and remote monitoring are provided. Testing options and their timing for postpartum screening in women who had GDM are also considered. Our suggestions are only applicable in a pandemic scenario; usual guidelines and care pathways should be re-implemented as soon as possible and appropriate."],"journal":"Eur J Endocrinol","authors":["Thangaratinam, Shakila","Cooray, Shamil D","Sukumar, Nithya","Huda, Mohammed S","Devlieger, Roland","Benhalima, Katrien","McAuliffe, Fionnuala","Saravanan, Ponnusamy","Teede, Helena"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454456","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1530/EJE-20-0401","topics":["Prevention"],"weight":1,"_version_":1667881798544130049,"score":9.490897,"similar":[{"pmid":32396397,"title":"Managing Diabetes in Pregnancy before, during and after COVID-19.","text":["Managing Diabetes in Pregnancy before, during and after COVID-19.","BACKGROUND: Pregnant women with diabetes are identified as being more vulnerable to the severe effects of COVID-19 and advised to stringently follow social distancing measures. Here we review the management of diabetes in pregnancy before and during the lockdown. METHODS: The majority of antenatal diabetes and obstetric visits are provided remotely, with pregnant women attending hospital clinics only for essential ultrasound scans and labour and delivery. On-line resources for supporting women planning pregnancy as well as for self-management of pregnant women with type 1 diabetes (T1D) using intermittent or continuous glucose monitoring (CGM) are provided. Retinal screening procedures, intrapartum care and the varying impact of lockdown on maternal glycaemic control are considered. Alternative screening procedures have for diagnosing hyperglycaemia during pregnancy and Gestational Diabetes (GDM) are discussed. Case histories describe the remote initiation of insulin pump therapy and automated insulin delivery in T1D pregnancy. RESULTS: Initial feedback suggests that video consultations are well received and that the patient experiences for women requiring face-to-face visits are greatly improved. As the pandemic eases, formal evaluation of remote models of diabetes education and technology implementation, including women's views, will be important. CONCLUSIONS: Research and audit activities will resume and we will find new ways for supporting pregnant women with diabetes to choose their preferred glucose monitoring and insulin delivery.","Diabetes Technol Ther","Murphy, Helen","32396397"],"abstract":["BACKGROUND: Pregnant women with diabetes are identified as being more vulnerable to the severe effects of COVID-19 and advised to stringently follow social distancing measures. Here we review the management of diabetes in pregnancy before and during the lockdown. METHODS: The majority of antenatal diabetes and obstetric visits are provided remotely, with pregnant women attending hospital clinics only for essential ultrasound scans and labour and delivery. On-line resources for supporting women planning pregnancy as well as for self-management of pregnant women with type 1 diabetes (T1D) using intermittent or continuous glucose monitoring (CGM) are provided. Retinal screening procedures, intrapartum care and the varying impact of lockdown on maternal glycaemic control are considered. Alternative screening procedures have for diagnosing hyperglycaemia during pregnancy and Gestational Diabetes (GDM) are discussed. Case histories describe the remote initiation of insulin pump therapy and automated insulin delivery in T1D pregnancy. RESULTS: Initial feedback suggests that video consultations are well received and that the patient experiences for women requiring face-to-face visits are greatly improved. As the pandemic eases, formal evaluation of remote models of diabetes education and technology implementation, including women's views, will be important. CONCLUSIONS: Research and audit activities will resume and we will find new ways for supporting pregnant women with diabetes to choose their preferred glucose monitoring and insulin delivery."],"journal":"Diabetes Technol Ther","authors":["Murphy, Helen"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396397","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1089/dia.2020.0223","topics":["Prevention"],"weight":1,"_version_":1666627828074938368,"score":492.59073},{"pmid":32396948,"title":"Telehealth for High-Risk Pregnancies in the Setting of the COVID-19 Pandemic.","text":["Telehealth for High-Risk Pregnancies in the Setting of the COVID-19 Pandemic.","As New York City became an international epicenter of the novel coronavirus disease 2020 (COVID-19) pandemic, telehealth was rapidly integrated into prenatal care at Columbia University Irving Medical Center, an academic hospital system in Manhattan. Goals of implementation were to consolidate in-person prenatal screening, surveillance, and examinations into fewer in-person visits while maintaining patient access to ongoing antenatal care and subspecialty consultations via telehealth virtual visits. The rationale for this change was to minimize patient travel and thus risk for COVID-19 exposure. Because a large portion of obstetric patients had underlying medical or fetal conditions placing them at increased risk for adverse outcomes, prenatal care telehealth regimens were tailored for increased surveillance and/or counseling. Based on the incorporation of telehealth into prenatal care for high-risk patients, specific recommendations are made for the following conditions, clinical scenarios, and services: (1) hypertensive disorders of pregnancy including preeclampsia, gestational hypertension, and chronic hypertension; (2) pregestational and gestational diabetes mellitus; (3) maternal cardiovascular disease; (4) maternal neurologic conditions; (5) history of preterm birth and poor obstetrical history including prior stillbirth; (6) fetal conditions such as intrauterine growth restriction, congenital anomalies, and multiple gestations including monochorionic placentation; (7) genetic counseling; (8) mental health services; (9) obstetric anesthesia consultations; and (10) postpartum care. While telehealth virtual visits do not fully replace in-person encounters during prenatal care, they do offer a means of reducing potential patient and provider exposure to COVID-19 while providing consolidated in-person testing and services. KEY POINTS: . Telehealth for prenatal care is feasible.. . Telehealth may reduce coronavirus exposure during prenatal care.. . Telehealth should be tailored for high risk prenatal patients..","Am J Perinatol","Aziz, Aleha","Zork, Noelia","Aubey, Janice J","Baptiste, Caitlin D","D'Alton, Mary E","Emeruwa, Ukachi N","Fuchs, Karin M","Goffman, Dena","Gyamfi-Bannerman, Cynthia","Haythe, Jennifer H","LaSala, Anita P","Madden, Nigel","Miller, Eliza C","Miller, Russell S","Monk, Catherine","Moroz, Leslie","Ona, Samsiya","Ring, Laurence E","Sheen, Jean-Ju","Spiegel, Erica S","Simpson, Lynn L","Yates, Hope S","Friedman, Alexander M","32396948"],"abstract":["As New York City became an international epicenter of the novel coronavirus disease 2020 (COVID-19) pandemic, telehealth was rapidly integrated into prenatal care at Columbia University Irving Medical Center, an academic hospital system in Manhattan. Goals of implementation were to consolidate in-person prenatal screening, surveillance, and examinations into fewer in-person visits while maintaining patient access to ongoing antenatal care and subspecialty consultations via telehealth virtual visits. The rationale for this change was to minimize patient travel and thus risk for COVID-19 exposure. Because a large portion of obstetric patients had underlying medical or fetal conditions placing them at increased risk for adverse outcomes, prenatal care telehealth regimens were tailored for increased surveillance and/or counseling. Based on the incorporation of telehealth into prenatal care for high-risk patients, specific recommendations are made for the following conditions, clinical scenarios, and services: (1) hypertensive disorders of pregnancy including preeclampsia, gestational hypertension, and chronic hypertension; (2) pregestational and gestational diabetes mellitus; (3) maternal cardiovascular disease; (4) maternal neurologic conditions; (5) history of preterm birth and poor obstetrical history including prior stillbirth; (6) fetal conditions such as intrauterine growth restriction, congenital anomalies, and multiple gestations including monochorionic placentation; (7) genetic counseling; (8) mental health services; (9) obstetric anesthesia consultations; and (10) postpartum care. While telehealth virtual visits do not fully replace in-person encounters during prenatal care, they do offer a means of reducing potential patient and provider exposure to COVID-19 while providing consolidated in-person testing and services. KEY POINTS: . Telehealth for prenatal care is feasible.. . Telehealth may reduce coronavirus exposure during prenatal care.. . Telehealth should be tailored for high risk prenatal patients.."],"journal":"Am J Perinatol","authors":["Aziz, Aleha","Zork, Noelia","Aubey, Janice J","Baptiste, Caitlin D","D'Alton, Mary E","Emeruwa, Ukachi N","Fuchs, Karin M","Goffman, Dena","Gyamfi-Bannerman, Cynthia","Haythe, Jennifer H","LaSala, Anita P","Madden, Nigel","Miller, Eliza C","Miller, Russell S","Monk, Catherine","Moroz, Leslie","Ona, Samsiya","Ring, Laurence E","Sheen, Jean-Ju","Spiegel, Erica S","Simpson, Lynn L","Yates, Hope S","Friedman, Alexander M"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396948","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1055/s-0040-1712121","locations":["New York","Manhattan","preeclampsia"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1666627828006780928,"score":266.74838},{"pmid":32401226,"title":"COVID-19 infection during pregnancy: fetus as a patient deserves more attention.","text":["COVID-19 infection during pregnancy: fetus as a patient deserves more attention.","The novel coronavirus disease 2019 (COVID-19) pandemic is causing concern also for the management and outcome of COVID-19-positive pregnant women and their offspring, as reported cases are rare. Current evidence suggests the association of COVID-19 infection in pregnancy with both severe maternal morbidity requiring intensive care and perinatal complications (preterm birth with consequent neonatal morbidity and even perinatal death). Most of the reported cases focused specifically on the maternal outcomes and possible vertical transmission, but less attention has been paid to fetus as a patient in such pregnancies. The use of antenatal steroids and fetal neuroprotection with magnesium sulfate is clearly underreported. Several recently issued guidelines suggest lowering the upper gestational age for antenatal steroid administration and also advocate extreme caution or even restraining from the use of magnesium sulfate. Also, the rate of cesarean deliveries among COVID-19 women is unacceptably high. Here we provide arguments for NOT changing the existing guidelines and caution against cesarean delivery that was the prevalent delivery mode in the reported cases and case series.","J Perinat Med","Stefanovic, Vedran","32401226"],"abstract":["The novel coronavirus disease 2019 (COVID-19) pandemic is causing concern also for the management and outcome of COVID-19-positive pregnant women and their offspring, as reported cases are rare. Current evidence suggests the association of COVID-19 infection in pregnancy with both severe maternal morbidity requiring intensive care and perinatal complications (preterm birth with consequent neonatal morbidity and even perinatal death). Most of the reported cases focused specifically on the maternal outcomes and possible vertical transmission, but less attention has been paid to fetus as a patient in such pregnancies. The use of antenatal steroids and fetal neuroprotection with magnesium sulfate is clearly underreported. Several recently issued guidelines suggest lowering the upper gestational age for antenatal steroid administration and also advocate extreme caution or even restraining from the use of magnesium sulfate. Also, the rate of cesarean deliveries among COVID-19 women is unacceptably high. Here we provide arguments for NOT changing the existing guidelines and caution against cesarean delivery that was the prevalent delivery mode in the reported cases and case series."],"journal":"J Perinat Med","authors":["Stefanovic, Vedran"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32401226","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1515/jpm-2020-0181","keywords":["covid-19","antenatal steroids","delivery mode","fetal neuroprotection","pregnancy"],"e_drugs":["Steroids","Magnesium Sulfate"],"weight":0,"_version_":1666714494780309504,"score":224.02455},{"pmid":32429722,"title":"Antenatal corticosteroids for pregnant women with COVID-19 infection and preterm prelabor rupture of membranes: a decision analysis.","text":["Antenatal corticosteroids for pregnant women with COVID-19 infection and preterm prelabor rupture of membranes: a decision analysis.","Background: While antenatal corticosteroids are routinely used to decrease adverse neonatal outcomes following preterm delivery, corticosteroids are also associated with worse outcomes in patients with viral respiratory infections. Currently in the setting of the COVID-19 pandemic, it is unclear whether antenatal corticosteroids for infant benefit outweigh the potential harm to a pregnant woman with a COVID-19 infection.Objective: To determine at which gestational ages administering antenatal corticosteroids is the optimal management strategy for hospitalized women with preterm prelabor rupture of membranes (PPROM) who have a COVID-19 infection.Methods: We designed a decision-analytic model to assess the maternal and infant outcomes associated with antenatal corticosteroid administration for risk of preterm delivery following rupture of membranes in the setting of a COVID-19 infection. We used a theoretical cohort of 10,000 women at each gestational age between 24 and 32 weeks who were hospitalized with PPROM and found to be COVID-19 positive. Maternal outcomes included intensive care unit admission and death related to COVID-19 infection. The infant outcomes of interest included respiratory distress syndrome, intraventricular hemorrhage, neurodevelopmental delay, and death, and were assessed along with maternal and infant quality-adjusted life years (QALYs). Deterministic and probabilistic sensitivity analyses were used to evaluate model assumptions.Results: In our theoretical cohort of 10,000 women with COVID-19 infection and preterm prelabor rupture of membrane between 24 and 32 weeks, corticosteroid administration resulted in 2,200 women admitted to the ICU and 110 maternal deaths at each gestational age. No antenatal corticosteroid use resulted in 1,500 ICU admissions and 75 maternal deaths at each gestational age. Antenatal corticosteroid administration also resulted in fewer cases of respiratory distress syndrome, intraventricular hemorrhage, and infant death. Overall, we found that between 24 and 30 weeks of gestation, administering antenatal corticosteroids was the optimal management strategy as it resulted in higher combined QALYs than no corticosteroid use. For 31 and 32 weeks of gestation, antenatal corticosteroid administration resulted in lower combined QALYs. On sensitivity analyses, we found that with increasing gestational age, the probability which antenatal corticosteroids was the optimal management strategy decreased.Conclusion: Administration of antenatal corticosteroids was an effective management strategy compared to no corticosteroid administration at gestational ages less than 31 weeks. These results provide data for clinicians to utilize when counseling pregnant patients hospitalized with PPROM and have a COVID-19 infection.","J Matern Fetal Neonatal Med","Zhou, Clarice G","Packer, Claire H","Hersh, Alyssa R","Caughey, Aaron B","32429722"],"abstract":["Background: While antenatal corticosteroids are routinely used to decrease adverse neonatal outcomes following preterm delivery, corticosteroids are also associated with worse outcomes in patients with viral respiratory infections. Currently in the setting of the COVID-19 pandemic, it is unclear whether antenatal corticosteroids for infant benefit outweigh the potential harm to a pregnant woman with a COVID-19 infection.Objective: To determine at which gestational ages administering antenatal corticosteroids is the optimal management strategy for hospitalized women with preterm prelabor rupture of membranes (PPROM) who have a COVID-19 infection.Methods: We designed a decision-analytic model to assess the maternal and infant outcomes associated with antenatal corticosteroid administration for risk of preterm delivery following rupture of membranes in the setting of a COVID-19 infection. We used a theoretical cohort of 10,000 women at each gestational age between 24 and 32 weeks who were hospitalized with PPROM and found to be COVID-19 positive. Maternal outcomes included intensive care unit admission and death related to COVID-19 infection. The infant outcomes of interest included respiratory distress syndrome, intraventricular hemorrhage, neurodevelopmental delay, and death, and were assessed along with maternal and infant quality-adjusted life years (QALYs). Deterministic and probabilistic sensitivity analyses were used to evaluate model assumptions.Results: In our theoretical cohort of 10,000 women with COVID-19 infection and preterm prelabor rupture of membrane between 24 and 32 weeks, corticosteroid administration resulted in 2,200 women admitted to the ICU and 110 maternal deaths at each gestational age. No antenatal corticosteroid use resulted in 1,500 ICU admissions and 75 maternal deaths at each gestational age. Antenatal corticosteroid administration also resulted in fewer cases of respiratory distress syndrome, intraventricular hemorrhage, and infant death. Overall, we found that between 24 and 30 weeks of gestation, administering antenatal corticosteroids was the optimal management strategy as it resulted in higher combined QALYs than no corticosteroid use. For 31 and 32 weeks of gestation, antenatal corticosteroid administration resulted in lower combined QALYs. On sensitivity analyses, we found that with increasing gestational age, the probability which antenatal corticosteroids was the optimal management strategy decreased.Conclusion: Administration of antenatal corticosteroids was an effective management strategy compared to no corticosteroid administration at gestational ages less than 31 weeks. These results provide data for clinicians to utilize when counseling pregnant patients hospitalized with PPROM and have a COVID-19 infection."],"journal":"J Matern Fetal Neonatal Med","authors":["Zhou, Clarice G","Packer, Claire H","Hersh, Alyssa R","Caughey, Aaron B"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32429722","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/14767058.2020.1763951","keywords":["antenatal corticosteroids","covid-19","decision analysis","preterm delivery","rupture of membranes"],"locations":["optimal","optimal"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667342288364240896,"score":210.79355},{"pmid":32396947,"title":"A Proposed Plan for Prenatal Care to Minimize Risks of COVID-19 to Patients and Providers: Focus on Hypertensive Disorders of Pregnancy.","text":["A Proposed Plan for Prenatal Care to Minimize Risks of COVID-19 to Patients and Providers: Focus on Hypertensive Disorders of Pregnancy.","Hypertensive disorders are the most common medical complications of pregnancy and a major cause of maternal and perinatal morbidity and death. The detection of elevated blood pressure during pregnancy is one of the cardinal aspects of optimal antenatal care. With the outbreak of novel coronavirus disease 2019 (COVID-19) and the risk for person-to-person spread of the virus, there is a desire to minimize unnecessary visits to health care facilities. Women should be classified as low risk or high risk for hypertensive disorders of pregnancy and adjustments can be accordingly made in the frequency of maternal and fetal surveillance. During this pandemic, all pregnant women should be encouraged to obtain a sphygmomanometer. Patients monitored for hypertension as an outpatient should receive written instructions on the important signs and symptoms of disease progression and provided contact information to report the development of any concern for change in status. As the clinical management of gestational hypertension and preeclampsia is the same, assessment of urinary protein is unnecessary in the management once a diagnosis of a hypertensive disorder of pregnancy is made. Pregnant women with suspected hypertensive disorders of pregnancy and signs and symptoms associated with the severe end of the disease spectrum (e.g., headaches, visual symptoms, epigastric pain, and pulmonary edema) should have an evaluation including complete blood count, serum creatinine level, and liver transaminases (aspartate aminotransferase and alanine aminotransferase). Further, if there is any evidence of disease progression or if acute severe hypertension develops, prompt hospitalization is suggested. Current guidelines from the American College of Obstetricians and Gynecologists (ACOG) and The Society for Maternal-Fetal Medicine (SMFM) for management of preeclampsia with severe features suggest delivery after 34 (0/7) weeks of gestation. With the outbreak of COVID-19, however, adjustments to this algorithm should be considered including delivery by 30 (0/7) weeks of gestation in the setting of preeclampsia with severe features. KEY POINTS: . Outbreak of novel coronavirus disease 2019 (COVID-19) warrants fewer office visits.. . Women should be classified for hypertension risk in pregnancy.. . Earlier delivery suggested with COVID-19 and hypertensive disorder..","Am J Perinatol","Barton, John R","Saade, George R","Sibai, Baha M","32396947"],"abstract":["Hypertensive disorders are the most common medical complications of pregnancy and a major cause of maternal and perinatal morbidity and death. The detection of elevated blood pressure during pregnancy is one of the cardinal aspects of optimal antenatal care. With the outbreak of novel coronavirus disease 2019 (COVID-19) and the risk for person-to-person spread of the virus, there is a desire to minimize unnecessary visits to health care facilities. Women should be classified as low risk or high risk for hypertensive disorders of pregnancy and adjustments can be accordingly made in the frequency of maternal and fetal surveillance. During this pandemic, all pregnant women should be encouraged to obtain a sphygmomanometer. Patients monitored for hypertension as an outpatient should receive written instructions on the important signs and symptoms of disease progression and provided contact information to report the development of any concern for change in status. As the clinical management of gestational hypertension and preeclampsia is the same, assessment of urinary protein is unnecessary in the management once a diagnosis of a hypertensive disorder of pregnancy is made. Pregnant women with suspected hypertensive disorders of pregnancy and signs and symptoms associated with the severe end of the disease spectrum (e.g., headaches, visual symptoms, epigastric pain, and pulmonary edema) should have an evaluation including complete blood count, serum creatinine level, and liver transaminases (aspartate aminotransferase and alanine aminotransferase). Further, if there is any evidence of disease progression or if acute severe hypertension develops, prompt hospitalization is suggested. Current guidelines from the American College of Obstetricians and Gynecologists (ACOG) and The Society for Maternal-Fetal Medicine (SMFM) for management of preeclampsia with severe features suggest delivery after 34 (0/7) weeks of gestation. With the outbreak of COVID-19, however, adjustments to this algorithm should be considered including delivery by 30 (0/7) weeks of gestation in the setting of preeclampsia with severe features. KEY POINTS: . Outbreak of novel coronavirus disease 2019 (COVID-19) warrants fewer office visits.. . Women should be classified for hypertension risk in pregnancy.. . Earlier delivery suggested with COVID-19 and hypertensive disorder.."],"journal":"Am J Perinatol","authors":["Barton, John R","Saade, George R","Sibai, Baha M"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396947","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1055/s-0040-1710538","locations":["preeclampsia"],"topics":["Prevention"],"weight":1,"_version_":1666627827935477762,"score":203.33415}]}